Impact of LDL-cholesterol Lowering on Platelet Activation
Status:
Terminated
Trial end date:
2020-02-04
Target enrollment:
Participant gender:
Summary
The primary goal is to assess the impact of Evolocumab therapy on platelet function of
familial hypercholesterolemia (FH) patients in a randomized, double blind study. Evolocumab
is a humanized monoclonal antibody that targets circulating PCSK9, increases hepatic LDL
receptor, decreases plasma LDL cholesterol and reduces risk of cardiovascular events.
Evolocumab (brand name Rapatha) has been approved by FDA along with diet and maximally
tolerated statin therapy in adults with FH or atherosclerotic heart or blood vessel problems,
who need additional lowering of LDL cholesterol.
The secondary goal is to determine if platelet activation or the response to Evolocumab
therapy is modified by rs3184504 polymorphism. The investigators believe that these
investigations will complement ongoing studies to demonstrate that Evolocumab reduces
athero-thrombotic risk and aid the decision-making as to whether Evolocumab can reduce the
atherothrombotic risk in acute coronary syndrome (ACS) patients.